|
InterMune Stage: Venture Date of Investment: 2000 Web Site : http://www.intermune.com Stock Symbol : NASDAQ: ITMN |
 |
InterMune, Inc. is an independent biopharmaceutical company focused on developing and commercializing innovative therapies in pulmonology and hepatology. The company was founded in 1999 with a strategy of acquiring clinical-stage products that could benefit from increased development and commercial focus within targeted therapeutic areas. Warburg Pincus led InterMune's second round of private financing in 2000 to help fund such product acquisitions and the execution of clinical trials for, and commercialization of, new product indications. The company’s pulmonology pipeline includes a Phase III program evaluating pirfenidone in idiopathic pulmonary fibrosis (IPF), a progressive disease characterized by inflammation and scarring of the lungs. In hepatology, InterMune is focused on developing a protease inhibitor, ITMN-191, for the treatment of hepatitis C, together with its partner, Roche. InterMune also sells Actimmune (interferon-gamma),w hich is approved for the treatment of two rare congenital disorders.
